Coordination polymers of various architectures built with mixed imidazole/benzimidazole and carboxylate donor ligands and different metal ions: syntheses, structural features and magnetic properties

Ten coordination polymers {[Cd(L1)2]}n (1), {[Cu(L1)2]}n (2), {[Cd2(L1)2(HCOO)2(H2O)]}n (3), {[Cd2(L1)4]·3H2O}n (4), {[Cd(L1)(CH3COO)]}n (5), {[Cd(L1)2(C5H5N)]·2.5H2O}n (6), {[Zn(L2)2]}n (7), {[Cd2(L2)4]·H2O}n (8), {[Cd3(L2)6(H2O)]·2EtOH·H2O}n (9) and {[Cd(L3)2]·2DMF·4H2O}n (10), where HL1 = 4-imidazole-1-yl-benzoic acid, HL2 = 3-imidazole-1-yl-benzoic acid and HL3 = 4-benzmidazole-1-yl-benzoic acid, have been synthesized under different experimental conditions. Their structures are determined by single-crystal X-ray diffraction analyses and further characterized by IR spectra, thermogravimetric (TG) and elemental analyses. The structure of 1 is a 2D → 2D (2D = two dimensional) interpenetrating network with (4,4) grid topology while 2 has an interesting Kagome structure. Compounds 4 and 6 crystallize in 4- and 3-fold interpenetrating diamondoid frameworks respectively. Compound 7 is a layered non-interpenetrating (4,4) grid network whereas 8 has an unprecedented self-penetrating structure with 2D framework. Compound 9 is a self-penetrating 3D structure while 10 crystallizes in a non-interpenetrating (4,4) square-grid with one-dimensional (1D) channels. From these results, it is demonstrated that the structures of the coordination polymers are strongly dependent on the geometry of L1, L2 and reaction conditions. Variable temperature magnetic susceptibility study of 2 has also been performed

India Hypertension Control Initiative—Hypertension treatment and blood pressure control in a cohort in 24 sentinel site clinics

Abstract The India Hypertension Control Initiative (IHCI) is a multi‐partner initiative, implementing and scaling up a public health hypertension control program across India. A cohort of 21,895 adult hypertension patients in 24 IHCI sentinel site facilities in four Indian states (Punjab, Madhya Pradesh, Maharashtra, and Telangana), registered from January 2018 until June 2019 were assessed at baseline and then followed up for blood pressure (BP) control and antihypertensive medication use. Among all registrations, 11 274 (51%) of the patients returned for a follow‐up visit between July 2019 and September 2019. Among patients returning for follow‐up, 26.3% had BP controlled at registration, and 59.8% had BP controlled at follow‐up (p < .001). The absolute improvement in BP control was more than two times greater in primary care (48.1 percentage point increase) than secondary care facilities (22.9 percentage point increase). Most IHCI patients received prescriptions according to state‐specific treatment protocols. This study demonstrates that a scalable public health hypertension control program can yield substantial BP control improvements, especially in primary care settings. However, high loss to follow‐up limits population health impact; future efforts should focus on improving systems to increase the likelihood that patients will return to the clinic for routine hypertension care